Fareston
- Name:
Fareston
- Company:
Orion Pharma (Ireland) Ltd
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may be renewed (B)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 17/02/21

Click on this link to Download PDF directly
Orion Pharma (Ireland) Ltd
 Ltd.jpg)
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 17 February 2021 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Information about the sodium content of the tablets added to section 4.4: This medicine contains less than 1 mmol (23 mg) sodium per tablet that is to say essentially ‘sodium-free’.
Updated on 17 February 2021 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Free text change information supplied by the pharmaceutical company
Information has been added about the sodium content of the tablets: This medicine contains less than 1 mmol (23 mg) sodium per tablet that is to say essentially ‘sodium-free’.
Updated on 27 November 2018 PIL
Reasons for updating
- Change to section 6 - manufacturer
Updated on 19 July 2017 SPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 19 July 2017 SPC
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 17 July 2017 PIL
Reasons for updating
- New PIL for new product
Updated on 17 July 2017 PIL
Reasons for updating
- Change to section 6 - date of revision
Updated on 12 September 2016 SPC
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 12 September 2016 PIL
Reasons for updating
- Addition of manufacturer
Updated on 18 February 2016 PIL
Reasons for updating
- Change to date of revision
Updated on 18 February 2016 SPC
Reasons for updating
- Change to section 6.3 - Shelf life
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 8 September 2015 SPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 7 September 2015 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change to side-effects
Updated on 10 September 2014 SPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 4 September 2014 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change to side-effects
Updated on 28 April 2014 PIL
Reasons for updating
- Correction of spelling/typing errors
Updated on 14 March 2014 SPC
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 4 March 2014 PIL
Reasons for updating
- Change to date of revision
Updated on 17 March 2011 PIL
Reasons for updating
- Change to date of revision
Updated on 16 April 2009 SPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
2. QUALITATIVE
Each tablet contains 60 mg toremifene (as citrate).
Excipients: 30 mg lactose per tablet.
For a full list of excipients, see section 6.1.
4. Clinical particulars
4.1 Therapeutic indications
First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.
Fareston is not recommended for patients with estrogen receptor negative tumours.
4.2 Posology and method of administration
Posology
The recommended dose is 60 mg daily.
Renal impaiment
No dose adjustment is needed in patients with renal insufficiency.
Hepatic impairment
Toremifene should be used cautiously in patients with liver impairment (see section 5.2).
Pediatric use
There is no relevant indication for use of Fareston in children.
Method of administration
Toremifene is administered orally. Toremifene can be taken with or without food.
4.3 Contraindications
- Pre-existing endometrial hyperplasia and severe hepatic failure are contra-indications in long-term use of toremifene.
- Hypersensitivity to toremifene or to any of the excipients.
- Both in preclinical investigations and in humans, changes in cardiac electrophysiology have been observed following exposure to toremifene, in the form of QT prolongation. For reasons of drug safety, toremifene is therefore contraindicated in patients with:
- Congenital or documented acquired QT prolongation
- Electrolyte disturbances, particularly in uncorrected hypokalaemia
- Clinically relevant bradycardia
- Clinically relevant heart failure with reduced left-ventricular ejection fraction
- Previous history of symptomatic arrhythmias.
Toremifene should not be used concurrently with other drugs that prolong the QT interval (see also section 4.5).
4.4 Special warnings and precautions for use
Gynaecological examination should be performed before treatment administration, closely looking at
pre-existing endometrial abnormality. Afterwards gynaecological examination should be repeated at
least once a year. Patients with additional risk of endometrial cancer, e.g. patients suffering from
hypertension or diabetes, having high
closely monitored (see also section 4.8).
Patients with a history of severe thromboembolic disease should generally not be treated with toremifene
(see also section 4.8).
Fareston has been shown to prolong the QTc interval on the electrocardiogram in some patients in a dose-related manner. The following information regarding QT-prolongation is of special importance (for contraindications see section 4.3).
A QT clinical study with a 5-arm parallel design (placebo, moxifloxacin 400 mg, toremifene 20 mg, 80 mg, and 300 mg) has been performed in 250 male patients to characterize the effects of toremifene on the QTc interval duration. The results of this study show a clear positive effect of toremifene in the 80 mg group with mean prolongations of 21 - 26 ms. Regarding the 20 mg group, this effect is significant as well, according to
Fareston should be used with caution in patients with ongoing proarrhythmic conditions (especially elderly patients) such as acute myocardial ischaemia or QT prolongation as this may lead to an increased risk for ventricular arrhythmias (incl. Torsade de pointes) and cardiac arrest (see also section 4.3).
If signs or symptoms that may be associated with cardiac arrhythmia occur during treatment with Fareston, treatment should be stopped and an ECG should be performed.
If the QTc interval is > 500 ms, Fareston should not be used.
Patients with non-compensated cardiac insufficiency or severe angina pectoris should be closely monitored.
Hypercalcemia may occur at the beginning of toremifene treatment in patients with bone metastasis and
thus these patients should be closely monitored.
There are no systematic data available from patients with labile diabetes, from patients with severely
altered performance status or from patients with cardiac failure.
Fareston tablets contain lactose (30 mg/tablet). Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
4.5 Interaction with other medicinal products and other forms of interaction
An additive effect on QT interval prolongation between Fareston and the following drugs and other medicinal products that may prolong the QTc interval cannot be excluded. This might lead to an increased risk of ventricular arrhythmias, including Torsade de pointes. Therefore co-administration of Fareston with any of the following medicinal products is contraindicated (see also section 4.3):
- antiarrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide) or
- antiarrhythmics class
- neuroleptics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride),
- certain antimicrobials agents (moxifloxacin, erythromycin IV, pentamidine, antimalarials particularly halofantrine),
- certain antihistaminics (terfenadine, astemizole, mizolastine),
- others (cisapride, vincamine IV, bepridil, diphemanil).
Drugs which decrease renal calcium excretion, e.g. thiazide diuretics, may increase the risk of
hypercalcaemia.
Enzyme inducers, like phenobarbital, phenytoin and carbamazepine, may increase the rate of toremifene
metabolism thus lowering the steady-state concentration in serum. In such cases doubling of the daily
dose may be necessary.
There is a known interaction between anti-estrogens and warfarin-type anticoagulants leading to a
seriously increased bleeding time. Therefore, the concomitant use of toremifene with such drugs should
be avoided.
Theoretically the metabolism of toremifene is inhibited by drugs known to inhibit the CYP 3A enzyme
system which is reported to be responsible for its main metabolic pathways. Examples of such drugs are
ketoconazole and similar antimycotics, erythromycin and troleandomycin. Concomitant use of those
drugs with toremifene should be carefully considered.
4.6 Pregnancy and lactation
Toremifene is recommended for postmenopausal patients.
There are no adequate data from the use of Fareston in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.
Fareston should not be used during pregnancy.
In rats, decreased body weight gain of the offspring during lactation was observed.
Fareston should not be used during lactation.
4.7 Effects on ability to drive and use machines
Toremifene has no influence on the ability to drive and use machines.
4.8 Undesirable effects
The most frequent adverse reactions are hot flushes, sweating, uterine bleeding, leukorrhea, fatigue,
nausea, rash, itching, dizziness and depression. The reactions are usually mild and mostly due to the
hormonal action of toremifene.
The frequencies of the adverse reactions are classified as follows:
Very common (≥1/10)
Common (≥1/100 to <1/10)
Uncommon (≥1/1,000 to <1/100)
Rare (≥1/10,000 to <1/1,000)
Very rare (<1/10,000), not known (cannot be estimated from the available data).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
System organ class |
Very common |
Common |
Uncommon |
Rare |
Very rare |
Neoplasms beningn, malignant and unspecified (including cysts and polyps) |
|
|
|
|
endometrial cancer |
Metabolism and nutrition disorders |
|
|
loss of appetite |
|
|
Psychiatric disorders |
|
depression |
insomnia |
|
|
Nervous system disorders |
|
dizziness |
headache |
|
|
Eye disorders |
|
|
|
|
transient corneal opacity |
Ear and labyrinth disorders |
|
|
|
vertigo |
|
Vascular disorders |
hot flushes |
|
thromboembolic events |
|
|
Respiratory, thoracic and mediastinal disorders |
|
|
dyspnoea |
|
|
Gastrointestinal disorders |
|
nausea, vomiting |
constipation |
|
|
Hepatobiliary disorders |
|
|
|
increase of transaminases |
jaundice |
Skin and subcutaneous tissue disorders |
sweating |
rash, itching |
|
|
alopecia |
Reproductive system and breast disorders |
|
uterine bleeding leukorrhea |
endometrial hypertrophy |
endometrial polyps |
endometrial hyperplasia, |
General disorders and administration site conditions |
|
fatigue oedema |
weight increase, |
|
|
Thromboembolic events include deep venous thrombosis, thrombophlebitis and pulmonary embolism (see also section 4.4).
Toremifene treatment has been associated with changes in liver enzyme levels (increases of transaminases) and in very rare occasions with more severe liver function abnormalities (jaundice).
A few cases of hypercalcaemia have been reported in patients with bone metastases at the beginning of toremifene treatment.
Endometrial hypertrophy may develop during the treatment due to the partial estrogenic effect of toremifene. There is a risk of increased endometrial changes including hyperplasia, polyps and cancer. This may be due to the underlying mechanism/estrogenic stimulation (see also section 4.4).
Fareston increases the QT interval in a dose-related manner (see also section 4.4).
4.9 Overdose
Vertigo, headache and dizziness were observed in healthy volunteer studies at daily dose of 680 mg. The dose-related QTc interval prolongation potential of Fareston should also be taken into account in cases of overdose. There is no specific antidote and the treatment is symptomatic.
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Anti-estrogens, ATC code: L02BA02
Toremifene is a nonsteroidal triphenylethylene derivative. As other members of this class, e.g. tamoxifen and clomifene, toremifene binds to estrogen receptors and may produce estrogenic, anti-estrogenic or both effects, depending upon the duration of treatment, animal species, gender, target organ and variable selected. In general, however, nonsteroidal triphenylethylene derivatives are predominantly anti-estrogenic in rats and man and estrogenic in mice.
In post-menopausal breast cancer patients, toremifene treatment is associated with modest reductions in both total serum cholesterol and low density lipoprotein (
Toremifene binds specifically to estrogen receptors, competitively with oestradiol, and inhibits estrogen-induced stimulation of
The anti-tumour effect of toremifene in breast cancer is mainly due to the anti-estrogenic effect, although other mechanisms (changes in oncogene expression, growth factor secretion, induction of apoptosis and influence on cell cycle kinetics) may also be involved in the anti-tumour effect.
5.2 Pharmacokinetic properties
Absorption
Toremifene is readily absorbed after oral administration. Peak concentrations in serum are obtained within 3 (range 2 - 5) hours. Food intake has no effect on the extent of absorption but may delay the peak concentrations by 1.5 - 2 hours. The changes due to food intake are not clinically significant.
Distribution
The serum concentration curve can be described by a biexponential equation. The half-life of the first (distribution) phase is 4 (range 2 - 12) hours, and of the second (elimination) phase 5 (range 2 - 10 ) days. The basal disposition parameters (CL and V) could not be estimated due to the lack of intravenous study. Toremifene binds extensively ( > 99.5 %) to serum proteins, mainly to albumin. Toremifene obeys linear serum kinetics at oral daily doses between 11 and 680 mg. The mean concentration of toremifene at steady-state is 0.9 (range 0.6 - 1.3) g/ml at the recommended dose of 60 mg per day.
Metabolism
Toremifene is extensively metabolised. In human serum the main metabolite is N-demethyltoremifene with mean half-life of 11 (range 4 - 20) days. Its steady-state concentrations are about twice compared to those of the parent compound. It has similar anti-estrogenic, albeit weaker anti-tumour activity than the parent compound.
It is bound to plasma proteins even more extensively than toremifene, the protein bound fraction being > 99.9 %. Three minor metabolites have been detected in human serum: (deaminohydroxy)toremifene, 4-hydroxytoremifene, and N,N-didemethyltoremifene. Although they have theoretically interesting hormonal effects, their concentrations during toremifene treatment are too low to have any major biological importance.
Elimination
Toremifene is eliminated mainly as metabolites to the faeces. Enterohepatic circulation can be expected. About 10 % of the administered dose is eliminated via urine as metabolites. Owing to the slow elimination, steady-state concentrations in serum are reached in 4 to 6 weeks.
Characteristics in patients
Clinical anti-tumour efficacy and serum concentrations have no positive correlation at the recommended daily dose of 60 mg.
No information is available concerning polymorphic metabolism. Enzyme complex, known to be responsible for the metabolism of toremifene in humans, is cytochrome P450-dependent hepatic mixed function oxidase. The main metabolic pathway, N-demethylation, is mediated mainly by CYP 3A.
Pharmacokinetics of toremifene were investigated in an open study with four parallel groups of ten subjects: normal subjects, patients with impaired (mean AST 57 U/L - mean
5.3 Preclinical safety data
The acute toxicity of toremifene is low with LD-50 in rats and mice of more than 2000 mg/kg. In repeated toxicity studies the cause of death in rats is gastric dilatation. In the acute and chronic toxicity studies most of the findings are related to the hormonal effects of toremifene. The other findings are not toxicologically significant. Toremifene has not shown any genotoxicity and has not been found to be carcinogenic in rats. In mice, estrogens induce ovarian and testicular tumours as well as hyperostosis and osteosarcomas. Toremifene has a species-specific estrogen-like effect in mice and causes similar tumours. These findings are postulated to be of little relevance for the safety in man, where toremifene acts mainly as an anti-estrogen.
Non clinical in vitro and in vivo studies have evidenced the potential of toremifene and its metabolite to prolong cardiac repolarisation and this can be attributed to the blockade of hERG channels.
In vivo, high plasma concentrations in monkeys caused a 24 % prolongation in QTc, which is in line with QTc findings in humans.
It is also to be noted that the Cmax observed in the monkeys (1800 ng/ml) is two-fold compared to the mean Cmax observed in humans at a daily dose of 60 mg.
Action potential studies in isolated rabbit heart have shown that toremifene induce cardiac electrophysiological changes which start to develop at concentrations approximately 10 fold compared to the calculated free therapeutic plasma concentration in human.
6.6 Special precautions for disposal
No special requirements.
7. MARKETING AUTHORISATION HOLDER
Orion Corporation
Orionintie 1
FIN-02200 Espoo
Finland
8. MARKETING AUTHORISATION NUMBERS
EU/1/96/004/001
EU/1/96/004/002
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
10. DATE OF REVISION OF THE TEXT
{MM/YYYY}
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http://www.emea.europa.eu/
Updated on 16 April 2009 PIL
Reasons for updating
- Improved electronic presentation
- Change to side-effects
- Change to date of revision
- Addition of marketing authorisation holder
- Change to improve clarity and readability
- Change to marketing authorisation holder address
- Change to further information section
Updated on 21 March 2006 SPC
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 21 March 2006 PIL
Reasons for updating
- Change to date of revision
Updated on 5 August 2004 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 20 June 2003 SPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Product subject to medical prescription which may be renewed (B)